SAN DIEGO, May 24, 2023 (GLOBE NEWSWIRE) — Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased Telephone and Data Systems, Inc. (NYSE: TDS, TDS-PV, TDS-PU) securities between May 6, 2022 and November 3, 2022. Telephone and Data Systems, Inc. is a diversified telecommunications company.
For more information, submit a form, email Aaron Dumas, Jr., or give us a call (800) 350-6003.
What is this Case About: Telephone and Data Systems, Inc. (TDS) Misled Investors Regarding its Subsidiaries’ Ability to Retain Customers
According to the complaint, United States Cellular (USCellular) operates as a majority-owned subsidiary of TDS. Throughout the class period, USCellular battled a systematic loss of “postpaid” customers. In response, defendants touted USCellular’s purported ability to address postpaid customer “churn” and attrition via tailored promotions and purported expense discipline. Notwithstanding, USCellular’s churn rate continued to worsen and the Company’s promotional activity decimated its profitability.
On November 4, 2022, defendants reported operating results for the third quarter of 2022. Defendants’ corrective disclosures revealed that not only was USCellular’s heavy promotional activity still failing to correct postpaid churn rate, but that the “offer structure” and its lack of “expense discipline” had, in fact, substantially eroded the Company’s profitability. On this news, the price of TDS securities plummeted. TDS’ common stock price declined $4.29 per share (more than 25%), from a closing price of $16.57 per share on November 3, 2022, to a close of $12.28 on November 4, 2022. TDS’ preferred shares trading under the symbol TDS-PV declined $0.96 per preferred share (more than 5%), from a closing price of $17.20 per preferred share on November 3, 2022, to a close of $16.24 on November 4, 2022. TDS’ preferred shares trading under the symbol TDS-PU also declined $1.01 per preferred share (more than 5%) over the same period.
What Now: Similarly situated shareholders may be eligible to participate in the class action against Telephone and Data Systems, Inc. Shareholders who want to act as lead plaintiff for the class must file their papers by July 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.
To be notified if a class action against Telephone and Data Systems, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
| Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com | https://www.facebook.com/RobbinsLLP/ https://www.linkedin.com/company/robbins-llp/ |
- Icahn Enterprises L.P. Investor Notification: Kessler Topaz Meltzer & Check, LLP Announces July 10, 2023 Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Icahn Enterprises L.P. - June 3, 2023
- FOX, FOXA INVESTOR NEWS: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fox Corporation Investors to Inquire About Class Action Investigation – FOX, FOXA - June 3, 2023
- Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1 - June 3, 2023
